logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11642391 B1

PDFFull Text
Date of Patent:
May. 09, 2023

Filed:

Aug. 04, 2015

Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same

Applicants:

Vascular Biosciences, San Diego, CA (US);

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US);

David Mann, San Diego, CA (US);

Erkki Ruoslahti, La Jolla, CA (US);

Masanobu Komatsu, La Jolla, CA (US);

Inventors:

David Mann, San Diego, CA (US);

Erkki Ruoslahti, La Jolla, CA (US);

Masanobu Komatsu, La Jolla, CA (US);

Assignee:

Vascular Biosciences, San Diego, CA (US);

Attorneys:

Lewis Kohn & Walker LLP

David M. Kohn

Kari Moyer-Henry

Primary Examiner:

Li N Komatsu

Int. Cl.
CPC ...
A61K 38/12 (2006.01); G16B 35/00 (2019.01); G16C 20/60 (2019.01); A61K 31/337 (2006.01); A61K 31/506 (2006.01); A61K 38/55 (2006.01); A61K 45/06 (2006.01); A61K 31/222 (2006.01); A61K 31/573 (2006.01); A61K 47/68 (2017.01); A61K 47/64 (2017.01); G01N 33/15 (2006.01); G16B 35/20 (2019.01); G16B 35/10 (2019.01); A61P 31/00 (2006.01); A61P 1/16 (2006.01); A61P 9/12 (2006.01); A61P 13/12 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); A61K 31/18 (2006.01); A61K 31/436 (2006.01); A61K 31/438 (2006.01); A61K 38/08 (2019.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 38/12 (2013.01); A61K 31/18 (2013.01); A61K 31/222 (2013.01); A61K 31/337 (2013.01); A61K 31/436 (2013.01); A61K 31/438 (2013.01); A61K 31/506 (2013.01); A61K 31/573 (2013.01); A61K 38/08 (2013.01); A61K 38/55 (2013.01); A61K 45/06 (2013.01); A61K 47/64 (2017.08); A61K 47/643 (2017.08); A61K 47/6811 (2017.08); A61K 47/6851 (2017.08); A61P 1/16 (2018.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); G01N 33/15 (2013.01); G01N 33/5008 (2013.01); G16B 35/00 (2019.02); G16B 35/10 (2019.02); G16B 35/20 (2019.02); G16C 20/60 (2019.02);
Abstract

Compositions and methods useful for delivery of targeted therapies for pulmonary arterial hypertension, sepsis, cancer and cachexia. The compositions and methods are based on peptide pharmacophores that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. Peptide pharmacophores may selectively target tumor vasculature, regenerating tissue, wounded tissue, inflamed tissue, fibrotic tissue, remodeled tissue, tissue characterized by elevated heparanase levels, and have the ability to internalize into such diseased cells.

Find Patent Forward Citations

Loading…